価格表

在庫・価格 : 2025年04月29日 23時55分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
COVID-19 Human IgM IgG ELISA Kit, Anti-Nucleocapsid Protein IgM IgG
データシート※最新のデータシートでない場合があります
RCOEL961-N CSPセルスペクト
セルスペクト株式会社
1 kit ¥140,000
(未発注)
追加

在庫・価格 : 2025年04月29日 23時55分 現在

COVID-19 Human IgM IgG ELISA Kit, Anti-Nucleocapsid Protein IgM IgG

  • 商品コード:RCOEL961-N
  • メーカー:CSP
  • 包装:1kit
  • 価格: ¥140,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Imai K et al. Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. J Med Virol 2021 May;93(5):3211-3218
Imai K et al
2021/01/01
PubMed
2 Kaku N et al. Performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients: A retrospective study in outbreak on a cruise ship. PLoS One 2021;16(9):e0257452
Kaku N et al
2021/01/01
PubMed
3 Ashenagar MS et al. Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. Vaccines (Basel) 2022 Mar;10(4)
Ashenagar MS et al
2022/01/01
PubMed
4 Funakoshi Y et al. Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination. Vaccines (Basel) 2022 Jun;10(6)
Funakoshi Y et al
2022/01/01
PubMed
5 Watanabe M et al. A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients. Vaccines (Basel) 2022 Oct;10(11)
Watanabe M et al
2022/01/01
PubMed
6 Funakoshi Y et al. Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration. Br J Haematol 2023 Aug;202(3):504-516
Funakoshi Y et al
2023/01/01
PubMed
7 Yamashita T et al. Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients. J Clin Med 2022 Jul;11(13)
Yamashita T et al
2022/01/01
PubMed
8 Nishikubo M et al. Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur-uracil as postoperative adjuvant chemotherapy. Surg Today 2023 Sep;53(9):1057-1063
Nishikubo M et al
2023/01/01
PubMed
9 Shibata H et al. Evaluation of the analytical performance of anti-SARS-CoV-2 antibody test kits distributed or developed in Japan. Bioanalysis 2022 Mar;14(6):325-340
Shibata H et al
2022/01/01
PubMed
10 Nagashima, H, et al., Analysis of Serum Antibody Level after COVID-19 Vaccine and Side Effects after Vaccine, Advances in Infectious Diseases, 2023, 13, 249-262.

PubMed
  • No.: 1
  • 文献情報:
    Imai K et al. Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. J Med Virol 2021 May;93(5):3211-3218
    Imai K et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Kaku N et al. Performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients: A retrospective study in outbreak on a cruise ship. PLoS One 2021;16(9):e0257452
    Kaku N et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Ashenagar MS et al. Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. Vaccines (Basel) 2022 Mar;10(4)
    Ashenagar MS et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Funakoshi Y et al. Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination. Vaccines (Basel) 2022 Jun;10(6)
    Funakoshi Y et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Watanabe M et al. A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients. Vaccines (Basel) 2022 Oct;10(11)
    Watanabe M et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Funakoshi Y et al. Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration. Br J Haematol 2023 Aug;202(3):504-516
    Funakoshi Y et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Yamashita T et al. Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients. J Clin Med 2022 Jul;11(13)
    Yamashita T et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Nishikubo M et al. Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur-uracil as postoperative adjuvant chemotherapy. Surg Today 2023 Sep;53(9):1057-1063
    Nishikubo M et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Shibata H et al. Evaluation of the analytical performance of anti-SARS-CoV-2 antibody test kits distributed or developed in Japan. Bioanalysis 2022 Mar;14(6):325-340
    Shibata H et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Nagashima, H, et al., Analysis of Serum Antibody Level after COVID-19 Vaccine and Side Effects after Vaccine, Advances in Infectious Diseases, 2023, 13, 249-262.

  • 備考:
  • 参照:
    PubMed